New perspectives in first-line therapy

At this year’s IASLC World Conference on Lung Cancer (WCLC 2025) in Barcelona, a poster on the FLAURA2 study was presented, which presented new data on combination therapy with osimertinib in first-line EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). The study showed that osimertinib in combination with chemotherapy consisting of pemetrexed with cisplatin or carboplatin reduced the risk of death by 23% compared to monotherapy with generally manageable side effects.